Skip to main content
Celularity's IND cleared to assess glioblastoma multiforme therapy

Celularity has gained FDA clearance for its investigational new drug application for its natural killer cell therapy CYNK-001 designed to treat glioblastoma multiforme. The company announced plans to launch their first-in-human clinical trial in the US to test CYNK-001 in patients with relapsed glioblastoma multiforme.

Full Story: